Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
bioprocessingtechnical
Bioprocessing is the set of manufacturing steps that use living cells or biological ingredients to make medicines, vaccines, diagnostics, or other biological products. Think of it as an assembly line where living systems, rather than machines, create the final product; variations in scale, consistency and cost directly affect a product’s ability to reach patients and generate revenue. Investors watch bioprocessing for its impact on production risk, regulatory approval and profit margins.
biopharmaceuticalmedical
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
cell and gene therapiesmedical
Cell and gene therapies are advanced medical treatments that aim to repair or replace damaged cells or genes within the body to treat diseases. They hold the potential to deliver long-lasting or even curative effects, similar to fixing a broken part of a machine rather than just covering up the problem. For investors, these therapies represent a rapidly growing area with the promise of transforming healthcare and creating significant market opportunities.
biomanufacturingtechnical
Making medicines, vaccines and other products using living cells or biological systems instead of purely chemical processes; it is the industrial-scale “cooking” of biological ingredients into finished medical products. Investors care because biomanufacturing determines how quickly and cheaply a company can deliver therapies, meet demand, pass regulatory checks and protect earnings—like a bakery’s ovens and recipes deciding how much bread it can sell and at what cost.
single-usetechnical
Single-use describes a product designed to be used one time and then discarded or destroyed, like a disposable cup or a single-use syringe. For investors, it matters because these items create repeat sales of consumables, carry different regulatory and safety standards than reusable products, and can influence manufacturing costs, supply chain needs, liability exposure, and environmental or disposal responsibilities that affect a company’s profitability and risk profile.
bench-to-pilot scaletechnical
Bench-to-pilot scale describes the process of moving a technology or manufacturing method from small, laboratory experiments (the "bench") to a larger, early-production setup (the "pilot") that mimics real-world conditions. Investors watch this transition because it tests whether a concept can be produced consistently, safely, and at a reasonable cost—like proving a home recipe works in a restaurant kitchen before opening for customers—affecting timelines, funding needs, and commercial risk.
next-generation sequencingtechnical
Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.
mass spectrometrytechnical
Mass spectrometry is a laboratory technique that identifies and measures chemicals by giving molecules an electrical charge and sorting them by how fast they move, like weighing and separating coins to see which kinds are present. For investors, its results are evidence used in drug development, quality control, food and environmental testing, and diagnostics, so clear mass-spec data can affect regulatory approval, product reliability, costs and market confidence.
New and expanded facilities provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing.
Asia is an emerging global hub for biopharmaceutical innovation, driven by increased demand for biologics, vaccines and cell and gene therapies. Thermo Fisher’s continued investment across the region supports this growth, enabling customers with access to world-class technologies, expertise and localized support to accelerate the delivery of life-changing therapies.
“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific. “By expanding our network in Korea, Singapore and India, we’re bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably.”
Empowering Innovation Across the Region
Thermo Fisher’s tri-hub network connects leading Bioprocess Design Centers in Incheon, Hyderabad and Singapore, accelerates process development and brings Thermo Fisher’s world-class expertise closer to customers throughout Asia.
Incheon, Korea: The newly expanded Bioprocess Design Center empowers deeper collaboration and innovation through advanced materials, technologies, and enhanced lab capabilities.
Hyderabad, India (Genome Valley): The new Bioprocess Design Center, developed in partnership with the Government of Telangana, offers collaborative spaces for process design, simulation and optimization. It enables customers to co-create and test bioprocesses using the latest single-use and hybrid systems, advancing India’s rapidly growing biomanufacturing ecosystem.
Singapore: This expanded facility provides access to bench-to-pilot scale bioprocessing, expert-led training and deep collaborations with Thermo Fisher’s technical teams to scale early-stage processes, supporting flexible and sustainable biomanufacturing.
Together, these centers ensure customers have direct access to innovation, training and technical expertise, enabling agility, scalability and faster time to market for biologics production.
Supporting Customers from Research to Commercialization
Thermo Fisher delivers breakthrough technologies across next-generation sequencing, mass spectrometry and advanced bioprocessing systems. The company’s end-to-end capabilities span life sciences, diagnostics, analytical instruments and pharma services, empowering customers throughout the biopharma value chain.
“Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production,” added Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific. “We are proud to contribute to the transformation of Asia’s biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond.”
To learn more about Thermo Fisher’s network of Bioprocess Design Centers, please visit www.thermofisher.com/bdc.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
